Gottlieb Provides Update One Year after the Cures Act

Drug Industry Daily
As research advances into the biological underpinnings of diseases such as cancer, the FDA is expecting to see more drugs providing more data demonstrating survival benefit earlier in product development, Commissioner Scott Gottlieb told lawmakers at a one-year follow-up hearing on the 21st Century Cures Act.

To View This Article:


Subscribe To Drug Industry Daily